Adler LA, Frick G, Yan B. A long-term, open-label, safety study of triple-bead mixed amphetamine salts (SHP465) in adults with ADHD. J Atten Disord. 2017:1087054717696770.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Washington, DC, American Psychiatric Association, 2013.
Anguera JA, Brandes-Aitken AN, Antovich AD, et al. A pilot study to determine the feasibility of enhancing cognitive abilities in children with sensory processing dysfunction. PLoS One. 2017;12(4):e0172616.
Arns M, Loo SK, Sterman MB, et al. Editorial Perspective: How should child psychologists and psychiatrists interpret FDA device approval? Caveat emptor. J Child Psychol Psychiatry. 2016;57(5):656-8.
Bhat V, Hechtman L. Considerations in selecting pharmacological treatments for attention deficit hyperactivity disorder. The Pharmaceutical Journal. 2016. Available at: https://www.pharmaceutical-journal.com/research/review-article/considerations-in-selecting-pharmacological-treatments-for-attention-deficit-hyperactivity-disorder/20200602.article. Accessed November 5, 2019.
Biederman J, Boellner SW, Childress A, et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: A double-blind, placebo-controlled, crossover analog classroom study. J Biol Psychiatry. 2007;62:970–976.
Biederman J, Fitzgerald M, Kirova AM, et al. Further evidence of morbidity and dysfunction associated with subsyndromal ADHD in clinically referred children. J Clin Psychiatry. 2018;79(5). pii: 17m11870.
Biederman J, Lindsten A, Sluth LB, et al. Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized, double-blind, placebo-controlled, proof-of-concept study. J Psychopharmacol. 2019;33(4):511-521.
Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, Lyne A, Scherer N; SPD503 Study Group. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121(1):e73-e84.
Briars L, Todd T. A review of pharmacological management of attention-deficit/hyperactivity disorder. J Pediatr Pharmacol Ther. 2016;21(3):192–206.
Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27(5);699-711.
Castellanos I, Kronenberger WG, Pisoni DB. Questionnaire-based assessment of executive functioning: psychometrics. Appl Neuropsychol Child. 2018;7(2):93–109.
CHADD. CHADD’s position on patient access to ADHD medications. Available at: https://chadd.org/advocacy-blog/chadds-position-on-patient-access-to-adhd-medications/. Accessed on: November 5, 2019.
Childress A, Newcorn J, Stark JG, et al. A single-dose, single-period pharmacokinetic assessment of an extended-release orally disintegrating tablet of methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2016;26:505–512.
Childress AC, Berry SA. The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. Postgrad Med. 2010;122:35–41.
Childress AC, Wigal SB, Brams MN, et al. Efficacy and safety of amphetamine extended-release oral suspension in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2018;28:306–313.
ClinicalTrials.gov. Centafanadine. NCT03605849. Available at: https://clinicaltrials.gov/ct2/show/NCT03605849. Accessed October 27, 2019.
ClinicalTrials.gov. OPC-64005. NCT03324581. Available at: https://clinicaltrials.gov/ct2/show/NCT03324581. Accessed October 28, 2019.
Coghill D. Debate: Are Stimulant Medications for Attention-Deficit/Hyperactivity Disorder Effective in the Long Term? (For). J Am Acad Child Adolesc Psychiatry. 2019 Oct;58(10):938-939.
Coghill DR, Banaschewski T, Nagy P, et al. Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe. CNS Drugs. 2017;31(7):625-638.
Cooper RE, Williams E, Seegobin S, et al. Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial. Eur Neuropsychopharmacol. 2017;27(8):795-808.
Danielson ML, Bitsko RH, Ghandour RM, et al. Prevalence of parent-reported ADHD diagnosis and associated treatment among U.S. children and adolescents, 2016. J Clin Child Adolesc Psychol. 2018;47(2):199–212.
Davidson F, Cherry K, Corkum P. Validating the Behavior Rating Inventory of Executive Functioning for children with ADHD and their typically developing peers. Appl Neuropsychol Child. 2016;5(2):127-37.
Dehbozorghi S, Bagheri S, Moradi K, et al. Efficacy and safety of tipepidine as adjunctive therapy in children with attention deficit/hyperactivity disorder: Randomized, double‐blind, placebo‐controlled clinical trial. Psychiatry Clin Neurosci. 2019 Jul 11. doi: 10.1111/pcn.12913. [Epub ahead of print]
Diamond A. Executive functions. Annu Rev Psychol. 2013;64:135–168.
Dopheide JA, Pliszka SR. Attention-deficit-hyperactivity disorder: an update. Pharmacotherapy. 2009;29(6):656-679.
Doshi JA, Hodgkins P, Kahle J, et al. Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. J Am Acad Child Adolesc Psychiatry. 2012;51(10):990-1002.
Elia J, Ungal G, Kao C, et al. Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling. Nat Commun. 2018;9(1):4.
Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010;19(4):353-64.
Faraone SV, Rostain AL, Montano B, et al. Systematic review: nonmedical use of prescription stimulants: risk factors, outcomes, and risk reduction strategies. J Am Acad Child Adolesc Psychiatry. 2019 Jul 18. pii: S0890-8567(19)30470-8.
FDA. Center for Drug Evaluation and Research; Adhansia XR® Product Label, Application Number: 212038. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212038Orig1s000lbl.pdf Accessed October 25, 2019.
Gilbert DL, Wang Z, Sallee FE, et al. Dopamine transporter genotype influences physiologic response to medication in ADHD. Brain. 2006;129(Pt 8):2038-2046.
Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41(2 Suppl):26S-49S.
Gualtieri CT, Johnson LG. ADHD: is objective diagnosis possible? Psychiatry (Edgmont). 2005; 2(11): 44–53.
Heinrich H, Gevensleben H, Strehl U. Annotation: neurofeedback-train your brain to train behaviour. J Child Psychol Psychiatry. 2007 Jan;48(1):3-16.
Hirsch O, Christiansen H. Factorial structure and validity of the quantified behavior test plus (Qb+©). Assessment. 2017 Dec;24(8):1037-1049.
Hong SB, Dwyer D, Kim JW, et al. Subthreshold attention-deficit/hyperactivity disorder is associated with functional impairments across domains: a comprehensive analysis in a large-scale community study. Eur Child Adolesc Psychiatry. 2014;23(8):627-36.
Hsu T, Cutler A, Childress A, et al. A pilot study of a novel monoamine triple reuptake inhibitor centanafadine SR (EB-1020 SR) in the treatment of ADHD in adults. Poster presented at the 53rd Annual Meeting of the American College of Neuropsychopharmacology. Phoenix, AZ.
Ibrahim K, Donyai P. Drug holidays from ADHD medication: international experience over the past four decades. J Atten Disord. 2015;19(7):551-68.
Kaplan G, Newcorn JH. Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder. Pediatr Clin North Am. 2011;58(1):99-120.
Karimi M, Haghshenas S, Rostami R. Neurofeedback and autism spectrum: A case study. Procedia-Social and Behavioral Sciences. 2011;30:1472-1475.
Konofal E, Zhao W, Laouénan C, et al. Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder. Drug Des Devel Ther.. 2014;8:2321-32.
Kux L. Determination That MOBAN (Molindone Hydrochloride) Tablets (5 Milligrams, 10 Milligrams, 25 Milligrams, 50 Milligrams, and 100 Milligrams) and Capsules (5 Milligrams, 10 Milligrams, and 25 Milligrams) Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register. 2013. Available at: https://www.federalregister.gov/documents/2013/11/06/2013-26550/determination-that-moban-molindone-hydrochloride-tablets-5-milligrams-10-milligrams-25-milligrams-50. Accessed October 29, 2019.
Johnson JK, Liranso T, Saylor K, et al. A phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (extended-release viloxazine) in children with ADHD. J Atten Disord. 2019 Mar 29:1087054719836159. doi: 10.1177/1087054719836159. [Epub ahead of print]
Lopez FA, Leroux JR. Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges. Atten Defic Hyperact Disord. 2013;5(3):249-265.
Lyons Usher AM, "Measures of Executive Functioning and Their Relation to Functional Outcomes in a Sample of Youth with Attention-Deficit/hyperactivity Disorder (add)" (2012). Dissertations. Paper 367.
Marzbani H, Marateb HR, Mansourian M. Neurofeedback: a comprehensive review on system design, methodology and clinical applications. Basic Clin Neurosci. 2016;7(2):143–158.
Mayes D, Calhoun L, Mayes D, Molitoris S. Autism and ADHD: overlapping and discriminating
symptoms. Research in Autism Spectrum Disorders. 2012; 6: 277-285.
McCarthy S, Neubert A, Man KKC, et al. Effects of long-term methylphenidate use on growth and blood pressure: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). BMC Psychiatry. 2018;18(1):327.
McGough JJ, Sturm A, Cowen J, et al. Double-blind, sham-controlled, pilot study of trigeminal nerve stimulation for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2019 Apr;58(4):403-411.e3.
Michelson D, Faries D, Wernicke J, et al; Atomoxetine ADHD Study Group. Atomoxetine in the treatment of children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108(5):E83.
Miklós M, Futó J, Komáromy D, Balázs J. Executive function and attention performance in children with ADHD: effects of medication and comparison with typically developing children. Int J Environ Res Public Health. 2019;16(20).
Molindone. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-2014 Feb 17. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31643787. Accessed October 29, 2019.
Nitsche MA, Paulus W. Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation. J Physiol. 2000 Sep 15;527 Pt 3:633-9.
O’Brien AM, Kivisto LR, Deasley S, Casey JE. Executive functioning rating scale as a screening tool for ADHD: independent validation of the BDEFS-CA. J Atten Disord. 2019 Aug 24:1087054719869834. doi: 10.1177/1087054719869834. [Epub ahead of print]
Pan MR, Huang F, Zhao MJ. A comparison of efficacy between cognitive behavioral therapy (CBT) and CBT combined with medication in adults with attention deficit/ hyperactivity disorder (ADHD). Psychiatry Res. 2019;279:23-33.
Pelham WE Jr, Manos MJ, Ezzell CE, et al. A dose-ranging study of a methylphenidate transdermal system in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2005;44:522–529.
Pliszka SR, Bernet W, Bukstein O, et al, for the American Academy of Child and Adolescent Psychiatry Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894–921.
Pliszka SR, Wilens TE, Bostrom S, et al. Efficacy and safety of HLD200, delayed-release and extended-release methylphenidate, in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2017;27:474–482.
Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942-948.
Posner J, Kass E, Hulvershorn L. Using stimulants to treat ADHD-related emotional lability. Curr Psychiatry Rep. 2014;16(10):478.
Powell L, Parker J, Harpin V. What is the level of evidence for the use of currently available technologies in facilitating the self‑management of difficulties associated with ADHD in children and young people? A systematic review. Eur Child Adolesc Psychiatry. 2018 Nov;27(11):1391-1412.
Rotem A, Danieli Y, Ben-Sheetrit J, et al. Apparent lack of practice effects in the Test of Variables of Attention (TOVA) in adult ADHD. Atten Defic Hyperact Disord. 2019 Mar;11(1):73-81.
Rowland AS, Skipper BJ, Umbach DM, et al. The prevalence of ADHD in a population-based sample. J Atten Disord. 2015;19(9):741–754.
Sadeh A, Pergamin L, Bar-Haim Y. Sleep in children with attention-deficit hyperactivity disorder: a metaanalysis of polysomnographic studies. Sleep Med Rev. 2006; 10: 381-398.
Salehinejad MA, Wischnewski M, Nejati V, et al. Transcranial direct current stimulation in attention-deficit hyperactivity disorder: A meta-analysis of neuropsychological deficits. PLoS One. 2019 Apr 12;14(4):e0215095.
Salehinejad MA, Wischnewski M, Nejati V, et al. Correction: Transcranial direct current stimulation in attention-deficit hyperactivity disorder: A meta-analysis of neuropsychological deficits. PLoS One. 2019 Aug 20;14(8):e0221613.
Sallee F, Lyne A, Wigal T, McGough JJ. Long-term safety of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(3):215-226.
Sasaki T, Hashimoto K, Tachibana M, et al. Tipepidine in children with attention deficit/ hyperactivity disorder: a 4-week, open-label, preliminary study. Neuropsychiatr Dis Treat. 2014;10:719-22.
Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158(7):1067-1074.
Scarpelli S, Gorgoni M, D’Atri, et al. Advances in Understanding the Relationship between Sleep and Attention Deficit-Hyperactivity Disorder (ADHD). J Clin Med. 2019 Oct 19;8(10). pii: E1737.
Shaw P, Lalonde F, Lepage C, et al. Development of cortical asymmetry in typically developing children and its disruption in attention deficit/hyperactivity disorder. Arch Gen Psychiatry. 2009;66(8):888-896.
Shaw P, Sharp WS, Morrison M, et al. Psychostimulant treatment and the developing cortex in ADHD. Am J Psych. 2009;166(1):58-63.
Sherman C, Ramsay R, Barrow K, Williams P. The truth about treating ADHD with cognitive behavioral therapy (CBT). ADDitude. 2019; Available at: https://www.additudemag.com/cognitive-behavioral-therapy-for-adhd/
Sierawska A, Prehn-Krstensen A, Moliadze V, et al. Unmet needs in children with attention deficit hyperactivity disorder—can transcranial direct current stimulation fill the gap? Promises and ethical challenges. Front Psychiatry. 2019 May 16;10:334.
Snyder SM, Rugino TA, Hornig M, et al. Integration of an EEG biomarker with a clinician's ADHD evaluation. Brain Behav. 2015 Apr;5(4):e00330.
Sprich SE, Burbridge J, Lerner JA, Safren SA. Cognitive-behavioral therapy for ADHD in adolescents: clinical considerations and a case series. Cogn Behav Pract. 2015 May ; 22(2): 116–126.
Stark JG, Engelking D, McMahen R, Sikes C. A randomized crossover study to assess the pharmacokinetics of a novel amphetamine extended-release orally disintegrating tablet in healthy adults. Postgrad Med 2016;128:648–655.
Steele M, Weiss M, Swanson J, et al. A randomized, controlled effectiveness trial of OROS-methylphenidate compare to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol. 2006;13(1):e50-62.
Stein MA, Snyder SM, Rugino TA, Hornig M. Commentary: Objective aids for the assessment of ADHD - further clarification of what FDA approval for marketing means and why NEBA might help clinicians. A response to Arns et al. (2016). J Child Psychol Psychiatry. 2016 Jun;57(6):770-1.
Steingard R, Taskiran S, Connor DF, et al. New formulations of stimulants: an update for clinicians. J Child Adolesc Psychopharmacol. 2019;29(5):324-339.
Stevens MC, Gaynor A, Bessette KL, Pearlson GD. A preliminary study of the effects of working memory
training on brain function. Brain Imaging Behav. 2016; 10: 387-407.
Stocks JD, Taneja BK, Baroldi P, Findling RL. A phase 2a randomized, parallel group, dose-ranging study of molindone in children with attention-deficit/hyperactivity disorder and persistent, serious conduct problems. J Child Adolesc Psychopharmacol. 2012;22(2):102-11.
Teicher MH, Lowen SB, Polcari A, et al. Novel strategy for the analysis of CPT data provides new insight into the effects of methylphenidate on attentional states in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2004;14(2):219–232.
Teuscher NS, Adjei A, Findling RL, et al. Population pharmacokinetics of methylphenidate hydrochloride extended-release multiple-layer beads in pediatric subjects with attention deficit hyperactivity disorder. Drug Des Devel Ther. 2015;9:2767.
Thapar A, Cooper M, Eyre O, Langley K. What have we learnt about the cause of ADHD? J Child Psychol Psychiatry. 2013;54(1):3-16.
Thapar A, Cooper M, Jefferies R, Stergiakouli E. What causes attention deficit hyperactivity disorder? Arch Dis Child. 2012;97(3):260-265.
Thomas R, Sanders S, Doust J, et al. Prevalence of attention deficit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics. 2015;135(4).
Tivers E. 25 great mobile apps for ADHD minds. ADDitude. 2019. Available at: https://www.additudemag.com/mobile-apps-for-adhd-minds/.
Virta M, Salakari A, Antila M, et al. Short cognitive behavioral therapy and cognitive training for adults with ADHD – a randomized controlled pilot study. Neuropsychiatr Dis Treat. 2010;6:443–453.
Visser SN, Danielson ML, Bitsko RH, et al. Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003–2011. J Am Acad Child Adolesc Psychiatry. 2014;53(1):34-46.
Volkow ND, Wang GJ, Kollins SH. Evaluating dopamine reward pathway in ADHD. JAMA. 2009;302(10):1084-1091.
Wang Q, Sourina O. Real-time mental arithmetic task recognition from EEG signals. IEEE Trans Neural Syst Rehabil Eng. 2013;21(2):225-32.
Wigal SB, Childress A, Berry SA, et al. Efficacy and safety of a chewable methylphenidate extended-release tablet in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2017;27:690–699.
Wigal TE, Newcorn JH, Handal N, et al. A double-blind, placebo-controlled, phase II study to determine the efficacy, safety, tolerability and pharmacokinetics of a controlled release (CR) formulation of mazindol in adults with DSM-5 attention-deficit/hyperactivity disorder (ADHD). CNS Drugs. 2018;32(3):289-301.
Wilens TE, Faraone SV, Biederman J. Attention-deficit/hyperactivity disorder in adults. JAMA. 2004;292(5):619-623.
Wilens TE. Mechanism of agents used for ADHD. J Clin Psychiatry. 2006;67(Suppl8)32-37.
Wolraich ML, Hagan JF Jr, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019 Oct;144(4). pii: e20192528.
Wolraich ML, McKeown RE, Visser SN, et al. The prevalence of ADHD: its diagnosis and treatment in four school districts across two states. J Atten Disord. 2014;18(7):563–575.
Yerys Be, Bertollo JR, Kenworthy L, et al. Brief Report: Pilot Study of a Novel Interactive Digital Treatment to Improve Cognitive Control in Children with Autism Spectrum Disorder and Co-occurring ADHD Symptoms. J Autism Dev Disord. 2019;49(4):1727-1737.